Bnf
Chapter 5 ~ Infections: Special Section 1 of 5
Chapter 5 ~ Infections Please refer to The Hillingdon Hospitals NHS Trust Antibiotic Guidelines, Policy number 233,
and Surgical Prophylaxis Policy, Policy number 234
Notifiable diseases Doctors must notify the consultant in communicable disease control when attending a patient suspected of
suffering from any of the diseases listed below:
5.1 Antibacterial drugs
5.1.1 Penicillins
5.1.1.2 Penicillinase-resistant penicillins TEMOCILLIN
Injection 1g
Non Policy Antibiotic Requires Microbiology Approval
5.1.1.3 Broad-spectrum penicillins AMOXICILLIN
PowderSF 3 g
CO-AMOXICLAV
SuspensionSF 400/57 in
5.1.1.4 Antipseudomonal penicillins PIPERACILLIN with
Injection 2g/250mg;
tazobactam (TAZOCIN®) 4g/500mg
TICARCILLIN with
Injection 3g/200mg
clavulanic acid (TIMENTIN®)
5.1.2 Cephalosporins and other beta-lactams CEFIXIME
Suspension 100mg in
Tablet 200 mg
CEFTAZIDIME
Injection 500mg; 1g; 2g
CEFTRIAXONE
Injection 250mg; 1g
CEFUROXIME
Injection 250mg; 1.5g
ERTAPENEM
Intravenous infusion
IMIPENEM with
Intravenous infusion
Cilastatin
MEROPENEM
Injection 500mg; 1g
5.1.3 Tetracyclines LYMECYCLINE
Capsule 408mg (=
MINOCYCLINE
Modified release
Chapter 5 ~ Infections: Special Section 2 of 5
capsule 100mg
Tablet 50mg;
OXYTETRACYCLINE
Tablet 250mg
5.1.3 Tetracyclines (contd.) TIGECYCLINE
Intravenous infusion
5.1.4 Aminoglycosides AMIKACIN
Injection 500mg in 2ml
GENTAMICIN
Intrathecal injection
TOBRAMYCIN
Injection 40mg in 1ml;
5.1.5 Macrolides AZITHROMYCIN
Capsule 250mg
For Obstetrics and Gynaecology For Genito Urinary Medicine
Suspension 200mg in
5.1.6 Clindamycin CLINDAMYCIN
Suspension 75mg in
5.1.7 Some other antibacterials CHLORAMPHENICOL Capsule 250mg
Injection 1g (as sodium
COLISTIN
Injection 1 million units
SULPHOMETHATE SODIUM DAPTOMYCIN
Intravenous infusion
FUSIDIC ACID
Suspension 250mg in
LINEZOLID
Intravenous infusion
Suspension 100mg in
Tablet 600 mg
SODIUM FUSIDATE
Intravenous infusion
Tablet 250mg
SPECTINOMYCIN
Injection 2g
Unlicensed Genito Urinary Medicine
TEICOPLANIN
Injection 200mg;
VANCOMYCIN
Capsule 125mg
Injection 500mg; 1g
5.1.8 Sulphonamides and trimethoprim CO-TRIMOXAZOLE
Intravenous infusion
Suspension 240mg in
Tablet 480mg;
Chapter 5 ~ Infections: Special Section 3 of 5
SULFADIAZINE
Injection 250mg in 1ml
Tablet 500mg
5.1.9 Antituberculous drugs RIFABUTIN
Capsule 150mg
5.1.10 Antileprotic drugs DAPSONE
Tablet 50 mg
For Dermatologist use For Genito Urinary Medicine
5.1.12 Quinolones MOXIFLOXACIN
Tablet 400mg
NALIDIXIC ACID
Tablet 500mg
OFLOXACIN
Tablet 200mg; 400mg
5.2 Antifungal drugs AMPHOTERICIN
Intravenous infusion
CASPOFUNGIN
Intravenous infusion
ITRACONAZOLE
Capsule 100mg
For Haematologist use Non Policy Antibiotic Requires
Solution 50mg in 5ml
For Haematologist use Non Policy Antibiotic Requires
TERBINAFINE
Tablet 250mg
VORICONAZOLE
Tablet 200mg
For Haematologist use Non Policy Antibiotic Requires
5.3 Antiviral drugs
5.3.1 HIV infection
Nucleoside reverse transcriptase inhibitors ABACAVIR
Oral solution 100mg in
Tablet 300mg
ABACAVIR with
Tablet 300mg abacavir /
lamivudine and
zidovudine (TRIZIVIR®) DIDANOSINE
Enteric coated capsule
EMTRICITABINE
Capsule 200mg
LAMIVUDINE
Oral solution 50mg in
Tablet 150mg
Tablet 100mg
For Chronic Hepatitis ‘B’ Use in accordance with NICE (TA96)
STAVUDINE
Capsule 30mg; 40mg
TENOFOVIR
Tablet 245mg
For Genito Urinary Medicine For chronic Hepatitis B
DISOPROXIL
TENOFOVIR
Tablet 245mg/100mg
DISOPROXIL with Emtricitabine (TRUVADA®)
Chapter 5 ~ Infections: Special Section 4 of 5
ZIDOVUDINE
Capsule 100mg; 250mg
Injection 200mg in 20ml
Oral solution 50mg in
ZIDOVUDINE with
Tablet 300mg/150mg
lamivudine (COMBIVIR®)
Protease inhibitors ATAZANAVIR
Capsule 100mg; 150mg
DARUNAVIR
Tablet 300mg
LOPINAVIR with
ritonavir (KALETRA®)
Film coated Tablet
Oral solution
RITONAVIR
Oral solutionSF 400mg
Soft capsule 100mg
SAQUINAVIR
Tablet (Invirase®)
Non-nucleoside reverse transcriptase inhibitors EFAVIRENZ
Capsule 200mg
Oral solutionSF 150mg
Tablet 600mg
NEVIRAPINE
Suspension 50mg in
Tablet 200mg
5.3.2 Herpesvirus infections
5.3.2.1 Herpes simplex and varicella-zoster infection FAMCICLOVIR
Tablet 250mg
For Ophthalmologist use For Genito Urinary Medicine
5.3.2.2 Cytomegalovirus FOSCARNET SODIUM Intravenous infusion
GANCICLOVIR
Intravenous infusion
VALGANCYCLOVIR
Tablet 450mg
5.3.3 Viral hepatitis
5.3.3.1 Chronic Hepatitis B ENTECAVIR
Tablet 500mcg, 1mg
Oral Solution 50mcg/ml
ADEFOVIR DIPIVOXIL Tablet 10mg
5.3.3.2 Chronic Hepatitis C TELAPREVIR
Tablet 375mg
BOCEPREVIR
Capsule 200mg
Chapter 5 ~ Infections: Special Section 5 of 5
5.3.4 Influenza OSELTAMIVIR
Capsule 30mg, 45mg,
Oral Suspension 60mg
in 5ml
ZANAMIVIR
Powder for inhalation
5.3.5 Respiratory syncytial virus PALIVIZUMAB
Injection 50mg; 100mg
RIBAVIRIN
Tablet 200mg
For Chronic Hepatitis ‘C’ Use in accordance with NICE (TA200)
5.4 Antiprotozoal drugs
5.4.1 Antimalarials CHLOROQUINE
Tablet 250mg (=155mg
PHOSPHATE
(AVLOCHLOR®) CHLOROQUINE
Syrup 68mg (= 50mg
SULPHATE
Tablet 200mg (= 150mg
MEFLOQUINE
Tablet 250mg
PRIMAQUINE
Tablet 7.5mg
Treatment of Malaria For Genito Urinary Medicine Unlicensed Medicine
PROGUANIL
Tablet 100mg
PROGUANIL
Tablet 100mg/250mg
HYDROCHLORIDE with atovaquone (MALARONE®) PYRIMETHAMINE
Tablet 25mg
PYRIMETHAMINE
Tablet 25mg/500mg
with sulfadoxine (FANSIDAR®) QUININE
Injection 300mg in 1ml,
DIHYDROCHLORIDE
5.4.8 Drugs for pneumocystis pneumonia PENTAMIDINE
Injection 300mg
Unlicensed Medicine For Genito Urinary Medicine
ISETIONATE
Nebuliser solution
5.5 Anthelmintics
5.5.5 Schistosomicides PRAZIQUANTEL
Tablet 500mg
5.5.8 Drugs for stronyloidiasis ALBENDAZOLE
Tablet 400mg
IVERMECTIN
Tablet 3mg; 6mg
Source: http://www.thh.nhs.uk/documents/_Departments/Formulary/Chapter05_Special.pdf
Stiff-Person Syndrome Following West Nile Fever Sharon Hassin-Baer, MD; Eilon D. Kirson, MD, PhD; Lester Shulman, PhD; Aron S. Buchman, MD; Hanna Bin, PhD;Musa Hindiyeh, PhD; Lea Markevich; Ella Mendelson, PhD Background: Stiff-person syndrome is a rare autoim- Result: The search revealed a stretch of 12 amino acids mune disorder associated with antibodies against glu-in the NS1 protei
Literaturverzeichnis Prevalence, Demographics and Risk Factors for Colic. AAEP Proceedings, Focus Equine Colic, Québec City, Canada http://www.pferd-aktuel .de/Wir-ueber-uns/Zahlen-Fakten 3. Tinker MK, White NA, Lessard P, Thatcher CD, Pelzer KD, Davis B, Carmel DK (1997): Prospective study of equine colic risk factors. Risk factors associated with development of diarrhea in horses after
A |B |C |
D |E |
F |G |
H |I |
J |K |
L |M |
N |O |P |Q |R |S |T |U |V |W |X |
Y |Z | 0-9 |